This particular bit of news leaves your friend Doc Gumshoe shaking his head in puzzlement. To wit, in the US it is expected that there will be a substantial shortage of physicians in the upcoming years. The American Association of Medical Colleges predicts that this shortage may reach about 122,000 physicians by the year […]
Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.” I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]
The only reason I accepted his invitation to circle the dance floor is that his latest foray into temptation has to do with pluripotent stem cells, a highly interesting, extremely complex, and promising area of serious scientific investigation. But before I attempt to follow Dr Sears’ complicated dance routine, there’s another bit of news that […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[Michael Jorrin, who I call “Doc Gumshoe,” is a longtime medical writer who writes on health and medicine topics for us from time to time. He is not a doctor, and his commentary is not investment-focused. He chooses his own topics, and, as with all our guest columnists, the words and opinions are his alone […]
Cancer Care: Where Are We and Where Are We Headed?
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
[Ed note: Following is another installment from our favorite medical scribe, “Doc Gumshoe” (no, he’s not a doctor). We feature Michael’s commentary every couple weeks or so, and his thoughts and words are his own. “Doc” doesn’t pick stocks, but FDA decisions are a huge driver of investment success for pharmaceutical and biotech companies and […]
Tidings, Mostly Glad
[ed note: We feature the musings of our favorite health and medicine writer, Michael Jorrin, a couple times a month, and we’ve taken the liberty of calling him “Doc Gumshoe” (he’s not a doctor). You’ll find no stock picks in his pieces, but hopefully will get plenty of insight into the medical matters he explains […]
Pros & Cons of Screening for Breast and Prostate Cancer
The old news, by now a couple of years old, is that the U. S. Preventive Services Task Force (USPSTF) has recommended against routine screening of women aged 40 to 49 years for breast cancer, and also recommended against screening for prostate cancer for men at any age using the prostate-specific antigen (PSA) test. The […]
Comments
20 years of Mamogram radiation causes breast cancer. the false positives leading to unecessary "treatment" are even wors...
Mike......interesting. I, too, am a recent member of Black Optics; actually, his Nucleus program. So, today, first tra...
Joinhttps://www.cytodyn.com/media/press-releases/detail/296/cytodyn-files-ind-and-protocol-for-phase-1b2-clinical the di...
Outstanding review. Another interesting potential therapy involves the CCR5 receptor on T-cells. This receptor function...
SAN DIEGO, Oct. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of ...
CytoDyn Announces Plan to Develop PRO 140 for Metastatic Triple-Negative Breast Cancer as Initial Oncology Indication. h...
My Daughter fought and lost her battle with Breast Cancer and the Braca-2 gene! She was diagnosed as triple negative.. ...
InMed CEO Eric Adams reveals info about their work with breast cancer on an interview with James West / MidasLetter, Apr...
I don't see this as Hyasynth as they are a private complamy not traded. All the clues leed to InMed Pharma. A look at so...
Appears to be INMED. My only concern is their website and last press release in May 2018 doesn't mention anything about ...
https://www.angelnexus.com/o/web/165728 Hello, did anyone notice that the above company is pumping In Med Pharmaceuti...
Medical Marijuana As A Potential Breast Cancer Treatment ... darkwebnews.com/drugs/medical-marijuana-potential-breast-c...
Just using google I ran into this: Zelda Therapeutics a medical cannabis biotechnology company has revealed medical mari...
If this is Mengels latest on the cure for breast cancer I can't figure it out either. Can't imagine something as newswo...
Does anyone know the ticker for the $1 stock that cures breast cancer?...
The C word terrifies us all. I'm sorry you had that experience. I think the cold reality is that all diseases affect ea...
Being a Breast Cancer Survivor,(early stage HR/PR Positive) I find this information concerning. Underwent a Lumpectomy, ...
#X-Cancer #TILs > Immune recognition of somatic mutations leading to complete durable regression in metastatic breast ca...
I am a firm believer in the value of the Primary Care Physician to the overall health care "system" (ironic laugh here)....
I believe that breast cancer treatment is going into Phase III. In the presentation they mention various milestone pay...
Took a position in $ONCYF today which is favorably viewed by KSS and Helen and Twitter. They have an upcoming presen...
Hi Porgie. I owned $SNDX for a while as well but sold out once I took another look at the phase 2 data for E2112 - HR+, ...
$OMCYF - Oncolytics Biotech(R) to Present REOLYSIN(R) at the 2018 Precision: Breast Cancer World R&D Summit 20180306 ...
Does anyone know the name of the company that has just successfully developed a cancer vaccine specifically for breast c...
$ONCYF np - 20180207; Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breas...
$CASC $SGEN “Seattle Genetics disappoints Puma bulls with Cascadian takeout” Date January 31, 2018 Why buy Pu...
ONCYF- NP as of yet. Data with Reolysin doubling the survival rate for metastatic breast cancer is off the chart good. ...
I missed this post earlier, but it is indeed Patriot One. The identity of the company was cracked the day the tease was...
Syndax Pharmaceuticals Is In For A Potentially Transformative 2018 Jan.25.18 | About: Syndax Pharmaceuticals, (SNDX) ...
$ONCS - long I still own ONCS. I'm very interested in hearing more of the bear argument. In truth, I'm low on portfo...
$liquidBiopsy $BIOC $AI $MachineLearning $NVDA “CancerSEEK: Blood Test That Detects Eight Common Cancers” Ale...
$ONCS, long. OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study OncoS...
$HALO I reference the following extract from BioPharma Dive Sept. 14, 2017 titled Bristol, Roche tap Halozyme for tech p...
My wife was considering HRT 15 - 20 years ago but was scared off by the reported results of increased risk of breast can...
$RDUS NP J.P. Morgan note. “The presentation focused on the company’s commercial asset, Tymlos, which launc...
I also agree with Myron's comments. I was diagnosed with breast cancer in 2016 and sought out natural treatment. I refus...
$SNDX NP Syndax initiated with a Buy at B. Riley FBR B. Riley FBR analyst Madhu Kumar started Syndax Pharmaceutical...
$SNDX small position. Calendar says $SNDX Syndax Breast Cancer Ph3 PFS data "1H '18" So, if data is good sometime in...
$ONCS np; vs. $ONCYF np. Dr. KSS, both of these SanDiego based companies indicate their product turns cold tumors hot t...
$ONCS (long, ow) https://ir.oncosec.com/press-releases/detail/1931/oncosec-provides-2018-business-outlook OncoSec ...
$ ONCS LONG 03-Jan-2018:08:00:00, OncoSec Provides 2018 Business OutlookComplete stage 1 enrollment of PISCES/KEYNO...
kirzli, sndx-I share your concern, but I hope that entinostat will have better results with advanced hormone receptor po...
$FreeCME HER2-Positive Breast Cancer Since we discuss this often on here, this is a link for any healthcare profession...
I agree 100 percent. $SNDX shares have been sucked into the general vague biotech downdraft of recent weeks and saw some...
$SNDX This is a stock that has been puzzling me. I just keeps dropping. Their Phase 3 trial of Entinostat plus Aromac...
Thank you Doc for another excellent well reasoned and laid out article. Yes, I agree with you - I have at least one pati...
$BIOC, $SNDX long Thanks for the Syndax suggestion. I have been watching and unsure if I should nibble as well. I did...
$ONCS LONG Dr. Alain Algazi will present the updated data in an oral poster presentation (P524) at the Society for I...
$ONCS I am so impressed how this wonderful investing group works. Within a few hours after our lead scientist (DR. K...
First, bear in mind the space has much to prove. HDACi's haven't exactly blazed a path yet. I regard entinostat as being...
NP $ RDUS Radius Health announces that the FDA has granted Fast Track designation for elacestrant; (34.61) El...
Long $CLRB ll.com: Cellectar Biosciences receives additional Japanese patent for CLR 131, CLR 125 Cellectar Bioscie...
genetic tests for cancer are also available--free!--to survivers with a nasty family history of breast cancer, which cov...
$NVS It's as simple as a selfie and a hashtag on Twitter to raise money for metastatic breast cancer. Novartis don...
$SNDX Syndax - Subscriber Eemajin asked me an interesting question about $SNDX catalysts on the Gummie Catalyst Calendar...
$double post I'm happy to have read it twice Nocitons. While I'm here, I'd love to know if you, Doc, saw the Venb...
Hi....I tend to agree with you. For home gamers, CASC is the former OncoThyreon, and tucatinib inhibits the tyrosine kin...
Alley A Snickers would do it !! Look at all the other benefits of MetFormin. My wife as a breast cancer survivor got on ...
I met with MYGN a few years ago while the stock was still on the southbound express. Their super success story test (pr...
To round out linling's post, the PT of $29 is essentially a tripling of where shares of $SNDX sit now. I acquired my ove...
$SNDX Interesting the analyst didn't even mention the Phase 3 breast CA (which is somewhat behind schedule) ECOG-ACR...
PARPi olaparib boosts PFS in germline-BRCA mutational breast cancer. http://www.nejm.org/doi/full/10.1056/NEJMoa1706450...
Hi all - I just want to quickly share a personal story that shows a side of "big pharma" you most likely will never hea...
$Stem Cell Therapy - Novel Approach A stem cell-based method created by University of California, Irvine scientists c...
I will move this catalyst for $SNDX Breast Cancer program from October to December and indicate the two possible dates. ...
In any case Jab, $SNDX has several shots on goal with its 3 study Immuno-Oncology program and the FDA Breakthrough Ther...
The October Breast Cancer Entinostat HR event for Syndax is from the FDA's Biopharmcatalyst.com which has this with a No...
$SNDX- Yes this is 2 separate data readouts. SNDX's Entinostat has a breast cancer trial going on as well as an Imunoonc...
$BIOC long - Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy ...
Good listen on emerging data for breast cancer treatment in the future. http://noveltargets.com/category/season-3/ Che...
Wow, Doc, anything to help Inflammatory Breast Cancer would be fantastic news. My wife is six years on from her diagnos...
One wonders if ABX464 linked to the CLRB compound could have a role in inflammatory breast cancer, which is a dreaded ho...
A colleague, an Asian Indian female (and yes males do get breast cancer on occasion), lived 15 years with stage IV disea...
Thank you for your detailed explanation (I'd give two thumbs up if I could) of why you doubt efficacy in the human trial...
Wendy, She has been on meds for MS for over 20 years. These included betaseron, copaxone for many years, and tysabri f...
My best to you and your wife also. Last October my wife was diagnosed with triple negative breast cancer that was very u...
Astrazeneca's olaparib looks like the real deal for BRCA-mutated breast cancer. http://www.medscape.com/viewarticle/881...
$RDUS Long I am long on RDUS for its osteoporosis drug abaloparatide-SC. It's gotten FDA approval and is currently ...
Essiac is A cure for breast cancer nurse Rene M. Caisse ,was persecuted for helping cure paitionts with it.To get the or...
$RDUS Long : Hello Doc and fellow gummies, Since the tymlos approval and amgen safety issues, the stock has had extreme...
$IMMU A post from 2014 by Dr. KSS had somewhat positive things to say about Immunomedics. Their drug for triple negative...
$SNDX The enrollment and release of interim data for their Phase 3 in breast cancer is behind schedule. "Based on ...
I belong to a group of fans that reads and suggests changes to novels of Mark Dawson, a British writer of 007 type ficti...
Dr., I have a very basic question that perhaps you could spend a few minutes on during the call if you think it would be...
$RDUS np Thanks for the reminder. I've been in and out of RDUS since Glenn & Doc first brought it to our attention....
Interesting points, but it's not clear to me that PPAR gamma agonism would support elaboration of breast cancer. I'm not...
$Coffee Ralph: Thanks so much for a great reading list! I promptly launched into a search for practical ways to remov...
$VBLT Long VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target TEL AVIV, Israel, April 04,...
$VBLT long - VBL Therapeutics has added a news release to its Investor Relations website. http://ir.vblrx.com/phoenix.z...
$SNDX: Syndax announces 5 poster presentations at AACR17 (Washington, D.C., April 1-4) Key Entinostat Posters of ...
$TSRO: Jeff, congrats. You should thank yourself for a smart decision, not me. I am currently out of the shares, but...
$SNDX long This was one of the 12 Biotechs of Xmas. In Doc's original write up, I believe at that time they expected so...
$ no-ticker Researchers believe they have found the key to drug resistance in most common type of breast cancer htt...
Novartis gets quick FDA nod with LEE011 for breast cancer. https://endpts.com/watch-out-pfizer-novartis-lee011-bags-q...
PARP Inhibitors bring hope to breast cancer patients.(Target cancer cells only and well tolerated) https://www.firstwor...
$AKAO, AUPH, PTLA, SNDX and VBLT long all. It always helps me when I read what others are doing/thinking, so I thought I...
$SNDX long Thanks for link Ben. The Phase 3 for breast cancer is slated 2h17. On their last call, I think they alluded ...
$SNDX, no position. I'm woefully behind on the threads and my own independent due diligence because I've started a new...
Tim, My mom survived breast cancer and my dad prostate cancer, so I can empathize. Surround yourself with as much famil...